Investor Briefing with James McDonnell – 3 August 2026
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO, James McDonnell, held an investor briefing...
Prescient Therapeutics: Explainer with CEO James McDonnell CEO James McDonnell, recorded a short video explaining...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics: Investor Briefing with CEO James McDonnell CEO James McDonnell, held a shareholder briefing...
Prescient Therapeutics Ltd (ASX:PTX) has highlighted continued progress across its oncology development pipeline during the...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.